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Abstract: The study objective was to determine the presence of MMP-7 in cancer tissue in correlation with its 
serum level in patients diagnosed with colorectal cancer (CRC). In 45 patients with CRC, MMP-7 expression was 
assessed immunohistochemically on FFPE slides in tumours (N = 37) and in the corresponding surgical margin 
sample. MMP-7 serum level was measured preoperatively. The expression of MMP-7 in cancer tissue was much 
stronger as compared to the normal intestinal mucosa. Also the level of MMP-7 in the serum of CRC patients 
was higher than in healthy subjects (N = 24) (p < 0.01). The tumour located in the colon showed higher expres-
sion of MMP-7 than CRCs located in the rectum (p < 0.05), whereas the higher MMP-7 serum level showed 
correlation with older age (p = 0.005), tumour size less than 5 cm (p < 0.05), higher Dukes’ stage (p < 0.05) 
and distant metastases (p < 0.05). The increased serum level of MMP-7 in CRC patients may indicate the pres-
ence of distant metastases. (Folia Histochemica et Cytobiologica 2013, Vol. 51, No. 3, 206–212)
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Introduction
Colorectal cancer (CRC) is the third most common 
malignancy worldwide in men and women [1]. Poland 
belongs to Central European countries with moderate 
morbidity rates, CRC is mainly a disease of developed 
Western countries [2]. CRC is the fourth leading 
cause of death, with prognosis indicating a growing 
trend [3]. The diagnosis is usually late and 5-year 
survival rate ranges from 90% for early cancers, 70% 
for regional, to 10% for distant metastatic cancers. 
Therefore, there are studies for new and effective 
markers that could detect CRC and for therapeutic 
purposes [4].
Carcinogenesis in the large intestine is a com-
plex, multi-stage process leading to excessive tissue 
proliferation that cannot be controlled by natural 
mechanisms due to predominance of cell proliferation 
over cell death. However, local neoplastic growth 
would not be possible without reconstruction of the 
extracellular matrix (ECM). Stromal degradation 
and looseness also allow migration of cancer cells 
and thus their dissemination, vascular invasion and 
formation of distant metastases. The reconstruction 
of the ECM involves a variety of digestive enzymes 
[5, 6]. However, a major role can be ascribed to me-
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talloproteinases, which are intensively investigated in 
carcinogenic processes. 
One of the most important metalloproteinases 
is MMP-7 due to its low molecular mass (28 kDa) 
and unique structure; it is also called matrilysin-1 
or PUMP-1 [7]. Physiologically, MMP-7 is found in 
ductal and glandular epithelium of many tissues, also 
in monocytes or mesangial cells [8–11]. On the other 
hand, its overexpression has been detected in various 
neoplastic lesions, including lung, prostate, stomach 
and colon cancer [12–15]. Active matrilysin-1 shows a 
proteolytic activity on the ECM components, such as 
collagen, elastin, laminin, proteoglycans, fibronectin 
and casein [9]. It is also able to activate other metallo-
proteinases (MMP-2 and MMP-9) affecting the ECM, 
which promotes invasion of cancer cells [16–18]. Apart 
from the digestion of the stroma, MMP-7 also takes 
part in other processes involved in the carcinogenesis 
through breakdown of the cell surface protein [19]. In 
this way, the enzyme can induce proliferation [19–21], 
and regulate apoptosis [22, 23], angiogenesis [24] and 
escape of cancer cells against the immune system [25].
The knowledge of the mechanisms that regulate 
carcinogenesis could help to predict the advance-
ment of neoplastic disease and, eventually, inhibit 
its progression. Therefore, we decided to detect the 
presence of MMP-7 in cancer tissue in correlation 
with its serum level in CRC patients and to analyse 
this protein as a potential marker in clinical practice. 
Material and methods
Patients. The study was carried out on a group of 45 patients 
with CRC (30 men and 15 women aged 34–86 years, mean 
66.8 ± 11.8, median 66) treated in the 2nd Department 
of General and Gastroenterological Surgery, Medical 
University of Bialystok, Poland, in the years 2007–2009. 
Colorectal cancers were diagnosed histopathologically as 
the adenocarcinoma type without the mucinous component 
in 40/45 patients and as the mucinous type in 5/45 patients. 
Histologically, the tumours were identified as moderately- 
(42/45 patients) or poorly-differentiated carcinomas (3/45 
patients). According to TNM classification, in one case 
tumour infiltration was limited to the submucosa (pT1), in 
4 cases the muscular layer was invaded (pT2) and in as many as 
40 cases the subserosa was involved (pT3). In 25/45 patients, 
there was local lymph node involvement and in 18/45 distant 
metastases were found, mainly in the liver, pancreas, lungs, 
kidneys, ovaries and uterine body. The surgical interventions 
were not preceded by chemotherapy or radiotherapy.
The blood (5 mL) of 45 colorectal cancer patients was 
drawn for clot prior to surgery. Blood serum was stored fro-
zen at –80°C immediately after separation by centrifugation 
until the assay was performed.
The control group consisted of 24 healthy subjects 
(13 men and 11 women aged 45–75 years, mean 55.7 ± 7.3, 
median 54.5). The blood was collected from control patients 
before colorectal cancer screening test — colonoscopy.
The study was approved by the local Bioethics Com-
mittee. Each patient gave written informed consent for 
participation in the study.
Immunohistochemistry. The expression of MMP-7 protein 
was determined in cancer tissue and normal tissue of the 
surgical margin of CRC patients (glandular and surface 
epithelium) by immunohistochemistry. The tissue material 
was obtained only from 37 patients. The study used archival 
material consisting of paraffin-embedded colorectal cancer 
tissues. The control group included samples of healthy mu-
cosa of the colon, collected from the resected unchanged 
intestinal fragments of the same patients (N = 37). For-
malin-fixed and paraffin-embedded tissue specimens were 
cut with a microtome into 4 µm sections and mounted on 
silinized glass slides. The sections were deparaffinized in 
xylene and hydrated in alcohols. The antigen retrieval was 
not performed. Endogenous peroxidase was blocked with 
3% hydrogen peroxide for 10 min. Protein blocking was 
done with a serum-free protein blocker (Novocastra, UK) to 
reduce non-specific binding of primary and secondary anti-
bodies. Next, they were incubated with murine monoclonal 
anti-human MMP-7 antibody (clone: 111433, R&D Systems, 
UK) in 1:500 dilution for 60 min. at room temperature. The 
primary antibody was specific for human pro- and active 
forms of MMP-7. The streptavidin-biotin reaction (Biotiny-
lated Secondary Antibody, Streptavidin-HRP, Novocastra, 
UK) was followed according to manufacturer’s protocol by 
visualization of the antigen-antibody complex using chromo-
gen 3,3-diaminobenzidine (DAB, Novocastra, UK). Nuclei 
were counterstained with hematoxylin.
Positive reaction for MMP-7 was observed in the cy-
toplasm of normal mucosa and in cancer cells. Positive and 
negative controls were performed according to the produ-
cer’s protocol (Novocastra, UK).
The expression of MMP-7 protein was assessed semiqu-
antitatively based on staining intensity, which was defined 
depending on visualization of the reaction at the respective 
microscopic magnifications. The expression was defined as 
strong when the reaction was visible at × 40 total magni-
fication, moderate — at × 100, poor — at × 200, lacking 
— when not visible at × 200. Since there were only 4 cases 
with lacking or poor reaction, they were treated as one group 
for statistical purposes.
Enzyme-linked immunoabsorbent assays (ELISA). MMP-7 
concentration was measured with a quantitative sandwich 
enzyme immunoassay (Human Total MMP-7 Quantikine 
ELISA Kit, R&D Systems, UK) according to the manufac-
turer’s protocol. The serum samples were diluted 2-fold. All 
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the specimens were assayed twice in duplicate. The MMP-7 
Quantikine ELISA kit detected both pro- and active forms 
of recombinant and normal human MMP-7. The results 
were presented in nanograms per millilitre.
Statistics. Statistical analysis was based on STATISTICA 
8.0 program (Statsoft, Cracow, Poland). Statistical analysis 
was conducted using Student’s t-test. The data distribution 
was normal according to Shapiro-Wilk W-test. The Man-
n-Whitney U-test was used to compare the two groups. 
Spearman’s correlation coefficient test was applied to find 
correlations of serum protein level with clinicopathological 
factors and morphological parameters of blood. The value 
of p < 0.05 was considered statistically significant. Missing 
data were removed in pairs. Additionally, the area under the 
ROC curve (AUC) was assessed using MedCalc statistical 
software (MedCalc Software, Ostend, Belgium). 
Results
Immunohistochemical expression of MMP-7 
in colorectal cancer
In normal mucosa membrane of the resected fragment 
of the large intestine, the expression of MMP-7 was 
either lacking or poor to moderate, and irregularly 
distributed in glands (Figure 1 A). In the colorectal 
cancer samples, the positive reaction was observed in 
the cytoplasm of cancer cells and identified as negative 
or poor in 4 patients, moderate in 18 and strong in 
15 cases (Figure 1 B, C, D). The statistical analysis 
showed no significant correlations of MMP-7 expres-
sion in cancer tissue with gender and age of patients, 
tumour grade, tumour stage (pT), Dukes’ classifica-
tion, lymph node involvement or distant metastases. 
A statistically significant correlation was found be-
tween tumour location in the colon and high expression 
of MMP-7 in cancer tissue. In rectal cancers, modera-
te expression of MMP-7 was predominant (p < 0.05; 
r = –0.355) (Table 1).
Serum MMP-7 levels of colorectal cancer and con-
trol patients
The serum concentration of MMP-7 in colorectal 
cancer patients ranged between 4.32 and 12.93 ng/mL 
(7.45 ± 1.88 ng/mL, mean and SD; N = 45), and was 
significantly higher than in healthy subjects (6.31 ± 
± 0.91 ng/mL, range 4.94-8.26, N = 24) (p < 0.01). The 
ROC curve showed that the cut-off point for MMP-7 
was at the level of 6.88 ng/mL (sensitivity 58.3% and 
specificity 87.5%). The area under the ROC curve 
for MMP-7 level was 0.710, which indicates mode-
A B
C D
Figure 1. Immunohistochemical expression of MMP-7. A. lack of expression of MMP-7 in normal mucosa (× 20); B. poor 
(× 20); C. moderate (× 40) and D. strong expression of MMP-7 in colorectal cancer cells (× 40)
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rate diagnostic potential of the test in CRC patients 
(Figure 2). 
Correlations between serum MMP-7 levels and 
clinicopathological parameters in colorectal cancer 
patients
The serum level of MMP-7 in CRC patients over 
60 years of age (mean 73.2 ± 7.4, median 74) was 
significantly higher than in the group of younger 
patients (> 60 years old, mean 52.9 ± 6.2, median 
54) (Table 2). Tumours > 5 cm in diameter were 
found to correlate with lower serum concentration 
of MMP-7, whereas those < 5 cm in diameter had 
higher matrilysin-1 level (Table 2). Moreover, the 
increased level of MMP-7 correlated with higher 
stage in Duke’s classification (Table 2). A positive 
correlation was also observed between the presence 
of distant metastases and higher serum MMP-7 level 
in CRC patients (Table 2). No statistically significant 
differences were noted between the serum level of 
MMP-7 and other clinicopathological parameters. 
Table 1. Correlations between imunohistochemical expression of MMP-7 in tumour tissue and clinicopathological para-
meters in colorectal cancer patients
Parameter MMP-7 expression in tumour
(Number of patients, percentage)
Absent/poor Medium Strong p value
Age < 60
≥ 60
0 (0%)
4 (16%)
8 (66.7%)
10 (40%)
4 (33.3%)
11 (44%)
NS
Gender Male
Female
4 (16.7%)
0 (0%)
12 (50%)
6 (46.1%)
8 (33.3%)
7 (53.9%)
NS
Localization Colon
Rectum
1 (4.3%)
3 (21.4%)
10 (43.5%)
8 (57.2%)
12 (52.2%)
3 (21.4%)
p < 0.05
r = –0.355
Adenocarcinoma type Non-mucinous
Mucinous
4 (11.8%)
0 (0%)
16 (47.1%)
2 (66.7%)
14 (41.1%)
1 (33.3%)
NS
Grade of malignancies 2
3
4 (11.4%)
0 (0%)
17 (48.6%)
1 (50%)
14 (40%)
1 (50%)
NS
Tumour size < 5cm
≥ 5cm
2 (9.5%)
2 (12.5%)
8 (38.1%)
10 (62.5%)
11 (52.4%)
4 (25%)
NS
pT stage 1
2
3
0 (0%)
0 (0%)
4 (12.6%)
1 (100%)
3 (75%)
14 (43.7%)
0 (0%)
1 (25%)
14 (43.7%)
NS
Duke stage A
B
C
D
0 (0%)
2 (20%)
0 (0%)
2 (14.4%)
2 (100%)
4 (40%)
6 (54.5%)
6 (42.8%)
0 (0%)
4 (40%)
5 (45.5%)
6 (42.8%)
NS
Lymph node metastases Absent
Present
3 (18.75%)
1 (4.8%)
8 (50%)
10 (47.6%)
5 (31.25%)
10 (47.6%)
NS
Distant metastases Absent
Present
2 (8.7%)
2 (14.4%)
12 (52.2%)
6 (42.8%)
9 (39.1%)
6 (42.8%)
NS
The immunoreactivity was assessed as described in Methods. Pearson’s correlation coeffi cient test. Missing data were removed in pairs. NS — non signifi cant
Figure 2. Area under the ROC curves for MMP-7 serum 
levels in differentiation between colorectal cancer patients 
and healthy subjects
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Also immunohistochemical expression of MMP-7 in 
cancer tissue did not correlate with its serum level in 
CRC patients (Table 2).
Correlations between serum MMP-7 levels and 
blood morphology parameters in colorectal cancer 
patients
The statistical analysis revealed a negative correlation 
between serum level of MMP-7 and serum glucose 
concentration in CRC patients (p < 0.01) (Table 3). 
However, any significant correlation was found 
between serum MMP-7 concentration and other 
parameters.
Discussion 
The current study confirmed the observations of other 
authors that MMP-7 expression in colorectal cancer 
tissues is markedly higher than in normal intestinal 
mucosa, which proves the involvement of this metallo-
proteinase in CRC growth [26–30]. Also the finding of 
enhanced MMP-7 mRNA confirmed the involvement 
[11, 31, 32]. The statistical analysis showed only a 
stronger relationship of MMP-7 overexpression with 
tumours located in the colon as compared to those 
in the rectum. However, we revealed no significant 
correlations between MMP-7 expression in tumour 
cells and CRC advancement, similarly to Gomes et al. 
[26], who used antibody that detected both pro- and 
active forms of MMP-7. However, investigations done 
by Wang et al. [33] proved the correlation of positive 
MMP-7 expression with tumour infiltration depth 
in the intestinal wall and with distant metastases. 
Ogawa et al. [34] noted that MMP-7 expression in 
lymphatic vessels is a useful parameter in predicting 
CRC metastases to the liver. They also showed that 
the assessment of matrilysin expression can help pro-
gnosticate the course of the disease. Koskensalo et al. 
[28] revealed a link between high MMP-7 reaction in 
cancer and worse prognosis during a 5-year follow-up. 
Also research data on mRNA MMP-7 expression are 
Table 2. Correlations between serum MMP-7 concentration and clinicopathological parameters in colorectal cancer 
patients
Parameter MMP-7 [ng/mL]
N Mean Range Coefficient p value
Age ≤ 60
> 60
15
30
6.58
7.88
4.99–11.77
4.32–12.93
 0.417 < 0.01
Gender Male
Female
28
17
7.16
7.92
4.32–11.77
5.20–12.93
–0.146 NS
Localization Colon
Rectum
26
19
7.41
7.50
4.32–12.93
4.99–11.77
 0.032 NS
Adenocarcinoma type Nonmucinous
Mucinous
40
5
7.53
6.80
4.99–12.93
4.32–9.06
–0.098 NS
Grade of malignancies 2
3
42
3
7.46
7.25
4.32–12.93
6.12–8.15
 0.000 NS
Tumour size < 5cm
≥ 5cm
26
17
7.84
6.80
5.36–11.77
4.32–12.93
–0.308 < 0.05
pT stage 1
2
3
 1
 4
40
5.52
7.13
7.53
5.52
5.71–10.76
4.32–12.93
 0.217 NS
Duke stage A
B
C
D
2
13
12
18
5.68
6.95
7.20
8.17
5.52–5.85
4.32–9.06
4.99–10.76
5.71–12.93
–0.324 <0.05
Lymph node metastases Absent
Present
20
25
6.82
7.95
4.32–9.06
4.99–12.93
 0.246 NS
Distant metastases Absent
Present
27
18
6.97
7.95
4.32–10.76
4.99–12.93
 0.312 <0.05
IHC expression of MMP-7 Poor
Medium
Strong
 4
18
15
8.29
6.86
7.86
8.20–8.48
4.32–12.93
5.35–10.76
 0.199 NS
Correlation coefficients were calculated by using Spearman’s correlation test. Missing data were removed in pairs. NS – not statistically significant.
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Table 3. Correlation between serum MMP-7 levels and 
blood morphology parameters in CRC patients
Parameter MMP-7
N Coefficient p value
Red Blood Cell Count 33 –0.272 NS
White Blood Cell Count 33 0.042 NS
PLT 33 –0.024 NS
Haematocrit 33 –0.243 NS
Haemoglobin 33 –0.228 NS
Sodium 33 –0.307 NS
Potassium 33 0.054 NS
Prothrombin time 32 –0.083 NS
Prothrombin index 30 0.070 NS
Total proteins 22 –0.285 NS
Albumins 20 –0.088 NS
Aspartate Transaminase 24 0.334 NS
Alanine Transaminase 24 0.250 NS
Glucose 17 –0.610 < 0.01
Urea 29 0.345 NS
Creatinine 26 –0.059 NS
NS; Spearman’s correlation coefficient test. Missing data were remo-
ved in pairs. NS — not statistically significant
in favour of this metalloproteinase as a biological 
marker of CRC aggression. RT-PCR investigations by 
Mori et al. [31] and Wan et al. [35] found a correlation 
of MMP-7 mRNA overexpression with advanced Du-
kes’ stage and the presence of metastases to the liver. 
Our immunohistochemical findings do not seem 
to indicate that MMP-7 is a CRC stage marker. Ho-
wever, according to the results, the assessment of its 
preoperative serum level can be such a marker. We 
demonstrated a correlation of the increased serum 
level of MMP-7 with higher Dukes’ stage and with 
distant metastases. Also Maurel et al. [36] observed 
elevated serum levels of MMP-7 in patients with 
advanced CRC as compared to non-metastatic CRC. 
Moreover, they showed MMP-7 to be an independent 
prognostic factor for survival in patients with advan-
ced CRC. On the other hand, Martinez-Fernandez 
et al. [37], found not only the correlation between 
increased serum level of MMP-7 and worse prognosis, 
but also revealed that MMP-7 predicts recurrence 
in curatively resected CRC patients. Additionally, 
similarly to our observations, they noted high serum 
level of MMP-7 in older CRC patients. 
We divided the study group of colorectal cancers 
into < 5 cm and > 5 cm tumours. Interestingly, we 
observed a correlation between the increased serum 
level of MMP-7 in CRC patients and tumours < 5 cm 
in diameter. However, literature data do not confirm 
this correlation.
We also examined correlations between serum 
levels of MMP-7 in CRC patients with other blood 
parameters. In our study, a rise in the level of MMP-7 
was associated with decreased blood glucose levels. 
Maurel et al. [36] showed a relationship between high 
serum level of MMP-7 in CRC patients and elevated 
parameters, such as LDH, ALP and CEA. Perhaps, 
MMP-7 affects these factors through involvement in 
some unknown mechanisms. 
We observed increased expression and level of 
MMP-7 both in immunohistochemical investigations 
and in ELISA, as compared to the control group. Al-
though we used the antibody detecting pro- and active 
forms of MMP-7 in both methods, we found no corre-
lation between the immunohistochemical expression 
of MMP-7 in cancer tissue and its blood serum level 
in CRC patients. Perhaps, the ratio of pro- and active 
forms of MMP-7 differs between tissue and serum in 
CRC patients, one of them having prognostic advanta-
ge over the other. Future investigations using specific 
antibodies or assessment of MMP-7 activity with zy-
mographic method might help elucidate this pheno-
menon. Nevertheless, MMP-7 should be considered 
as an important factor in the carcinogenic process, 
especially, as a marker of the disease advancement that 
can be determined with a simple noninvasive ELISA 
method. The current study seems to confirm and extend 
earlier analyses of other authors concerning MMP-7 
expression in CRC, indicating possible use of MMP-7 
as a prognostic marker of CRC. 
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